San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
... 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced ...
... 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced ...
5. Discovery Platforms
(Oncology (it))
Kinase Platform Kinases are one of the most important drug target classes in several therapeutic areas, and particularly in Oncology, with >30 drugs already approved for a wide variety of solid tumors ...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib ...
San Diego - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib in overcoming resistance ...
... drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, ...
... drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, ...
... biotechnology company which is developing a range of innovative antibody-based therapeutics with antibody drug conjugate (ADCs) and immuno-oncology approaches for the treatment of cancer. The company’s ...
... biotechnology company which is developing a range of innovative antibody-based therapeutics with antibody drug conjugate (ADCs) and immuno-oncology approaches for the treatment of cancer. The company’s ...
... of Nerviano.   Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: “We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) ...
... of Nerviano.   Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: “We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) ...
Nerviano, Italy – October 28, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma were disclosed in a poster ...
Nerviano, Italy – September 29, 2014 - Nerviano Medical Sciences’ partner Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, presented interim results from the first-in-human ...
August 4, 2014 - San Diego, CA, USA & Nerviano, Italy --(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a ...
... in patients with advanced solid tumors with relevant molecular alterations will be disclosed at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.   Presentation title: Phase ...
... results of Miciclib in patients with thymic carcinoma will be reported at the 2014 American Society of Clinical Oncology (ASCO) annual meeting. Presentation title: A phase II study of milciclib (PHA-848125AC) ...
... these articles at the following link: http://www.nervianoms.com/en/oncology-en/publications.html        ...
Medicinal Chemistry and all of Oncology’s integrated chemical core technologies are set up to provide the synthetic chemistry output and medicinal chemistry competence for effectively advancing the drug ...
21. Core services
(CLIOSS (it))
... to EVMPD via EV-Web Acknowledgment Management Clinical Data Management Data Management Plan Case Report Form, Design and Development (extensive library of Oncology specific modules available) ...
22. Partnerships
(CLIOSS (it))
Partnership with Lombardy Oncology Network (Rete Oncologica Lombarda) and Lombardy Hematology Network (Rete Ematologica Lombarda). Partnership with renowned European and US development sites: ...
23. Expertise
(CLIOSS (it))
... experience in oncology clinical development from cytotoxics to hormonals and targeted therapies: INDICATIONS Acute Leukemia Chronic Leukemia Multiple Myeloma Myelodisplastic Syndromes ...
... a full range of clinical developments services to Healthcare Players thanks to the scientific heritage in oncology derived from Nerviano’s research site and to its team of professionals with a wide experience ...
25. Licensing e collaborazioni
(NMS Company (it))
...  Nerviano Medical Sciences and Genentech joint strenghts Nerviano Medical Sciences expands partnership with ChemDiv in lead discovery Brostallicin, the new oncology drug candidate, discovered by ...
26. Capabilities
(Oncology (it))
Our expanding discovery and development capabilities array includes classical and innovative approaches to drug discovery, fully integrated within the Oncology division.  ...
27. Purinome platform
(Technology Platforms (it))
The generation of novel chemotypes in support of our oncology research projects expanded in recent years from a canonical design of kinase targeted compound libraries to a broader interpretation of purinome ...
28. Kinase patform
(Technology Platforms (it))
Our Oncology unit has developed a methodological platform to discover small molecule kinase inhibitors, which we refer to as the ‘Kinase Platform’. A panel of over 90 cloned and expressed kinases is ...
29. Danusertib
(Pipeline (it))
... Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors, Journal of Clinical Oncology 2009,27:30(5094-5101) A phase I dose-escalation study of danusertib (PHA-739358) administered as ...
30. Nemorubicin
(Pipeline (it))
... Oncology Annual Meeting 2009,May 31(Abs 4593) Sun Y,Yang J, Luo P, et al. Efficacy of Nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary ...
31. Pubblicazioni NMS
(Science Corner (it))
... animal models for in vivo target identification and validation in oncology Texido G Methods Mol Biol (2013), (986), 281-305 View abstract on PubMed Antitumor efficacy on glioma models ...
32. Seminari di Oncologia
(Science Corner (it))
We are glad to host external speakers to present their latest findings at our Oncology Seminars Series. Usual topics include themes related to the biology of cancer, chemical approaches, and in general ...
33. Eventi e congressi
(Science Corner (it))
... Oncology Madrid , Spain Web link  ...
Nerviano – 15 March, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Nerviano – 18 January, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Before the Italian Ambassador to Washington, Giulio Terzi di Sant'Agata, the current Chairman of Nerviano Medical Sciences, Alberto Sciumè, and John DeYoung, Vice President Oncology Business Development ...
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed ...
... the clinical experimentation of our Cdc7 inhibitor - explains Dr. Francesco Colotta, NMS Oncology VP - first of all represents an acknowledgment of the quality and innovation of Italian research in the ...
Nerviano, 21 October, 2008 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
... in these days at the American Society of Clinical Oncology (ASCO) Conference, being held in Chicago from 30th May to 3rd June. For these three new compounds the scientists' attention will be called ...
... at Nerviano Medical Sciences Srl. (NMS), one of the leading oncology R&D companies in Europe. The article focuses on a new anti-cancer molecule that inhibits Cdc7, a target protein implicated in ...
... largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two ...
... (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced an agreement with Genentech, ...
... facility in Italy and one of the largest oncology-focused, integrated discovery and development organizations in Europe. It was incorporated in May 2004 following a spin-off from Pfizer.Today NMS is a ...
... a privately held oncology company, in a stock for stock merger valued at $20 million. SMi stockholders could also receive a maximum of $15 million in additional consideration, payable in either cash or ...
... stage development of active compounds against new oncology targets provided by Bristol-Myers Squibb. Terms of the multi-year risk sharing collaboration include the potential for up to $150 million in clinical ...
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.